Indian Journal of Cancer
Medknow Publications on behalf of Indian Cancer Society
Vol. 44, No. 3, 2007, pp. 93-98
Bioline Code: cn07015
Full paper language: English
Document type: Research Article
Document available free of charge
Indian Journal of Cancer, Vol. 44, No. 3, 2007, pp. 93-98
© Copyright 2007 Indian Journal of Cancer.
Clinico-biologic profile of Langerhans cell histiocytosis: A single institutional study|
Narula, G.; Bhagwat, R.; Arora, B.; Banavali, S.D.; Pai, S.K.; Nair, C.N.; Seth, T.; Laskar, S.; Muckaden, M.A.; Kurkure, P.A. & Parikh, P.M.
Context: Langerhans cell histiocytosis (LCH) is a rare atypical cellular disorder characterized by clonal proliferation of Langerhans cells leading to myriad clinical presentations and highly variable outcomes. There is a paucity of Indian studies on this subject.
Aim: To present the experience of management of LCH at a single institution.
Settings and Design: This is a retrospective observational study of patients with LCH who presented at the Tata Memorial Hospital between January 1987 and December 2002.
Materials and Methods: Fifty-two patients with LCH were treated in the study period. Due to the long observation period and variability in diagnostic and therapeutic protocols, the patients were risk-stratified based on present criteria. The disease pattern, management approaches and treatment outcomes of patients were recorded.
Statistical Analysis Used: Statistical analyses were done using Student′s ′t′ test, test for proportion and survival estimates based on the Kaplan-Meier method.
Results: The median age at presentation was 3 years and more than 48% of the patients had Group I disease. Skeleton, skin and lymphoreticular system were the commonly involved organs. Majority (80%) required some form of therapy. The projected overall survival is 63% at 10 years and mean survival is 118 months. Seventeen percent of surviving patients developed long-term sequelae.
Conclusions: The clinico-biologic profile of LCH patients in India is largely similar to international patterns except a higher incidence of lymphoreticular involvement. Majority of the patients respond favorably to therapy and have a good outcome, except a subset of Group I patients who warrant enrolment in clinical trials with innovative therapeutic strategies to improve outcome.
Clinical profile, Langerhans cell histiocytosis, outcome
Alternative site location: http://www.indianjcancer.com/